WO2006100679A3 - Anticorps de recombinaison diriges contre la transglutaminase humaine de type ii et utilisations de ces anticorps - Google Patents

Anticorps de recombinaison diriges contre la transglutaminase humaine de type ii et utilisations de ces anticorps Download PDF

Info

Publication number
WO2006100679A3
WO2006100679A3 PCT/IL2006/000368 IL2006000368W WO2006100679A3 WO 2006100679 A3 WO2006100679 A3 WO 2006100679A3 IL 2006000368 W IL2006000368 W IL 2006000368W WO 2006100679 A3 WO2006100679 A3 WO 2006100679A3
Authority
WO
WIPO (PCT)
Prior art keywords
transglutaminase
antibodies against
against human
recombinant antibodies
human type
Prior art date
Application number
PCT/IL2006/000368
Other languages
English (en)
Other versions
WO2006100679A2 (fr
Inventor
Roberto Marzari
Daniele Sblattero
Original Assignee
Quark Biotech Inc
Qbi Entpr Ltd
Roberto Marzari
Daniele Sblattero
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Biotech Inc, Qbi Entpr Ltd, Roberto Marzari, Daniele Sblattero filed Critical Quark Biotech Inc
Publication of WO2006100679A2 publication Critical patent/WO2006100679A2/fr
Publication of WO2006100679A3 publication Critical patent/WO2006100679A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à des anticorps spécifiques qui sont capables d'inhiber l'activité enzymatique de la TGase II. La présente invention se rapporte également à une composition pharmaceutique comportant en tant qu'ingrédient actif un anticorps tel que celui décrit ci-dessus, qui est utile pour le traitement ou la prévention des maladies de type fibrose, des troubles de cicatrisation ou des pathologies associées à des fibroses. Une telle composition pharmaceutique peut s'avérer utile pour traiter à la fois des formes aiguës et chroniques de fibroses d'organes.
PCT/IL2006/000368 2005-03-22 2006-03-22 Anticorps de recombinaison diriges contre la transglutaminase humaine de type ii et utilisations de ces anticorps WO2006100679A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66423805P 2005-03-22 2005-03-22
US60/664,238 2005-03-22
US68900605P 2005-06-08 2005-06-08
US60/689,006 2005-06-08

Publications (2)

Publication Number Publication Date
WO2006100679A2 WO2006100679A2 (fr) 2006-09-28
WO2006100679A3 true WO2006100679A3 (fr) 2007-03-29

Family

ID=37024230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2006/000368 WO2006100679A2 (fr) 2005-03-22 2006-03-22 Anticorps de recombinaison diriges contre la transglutaminase humaine de type ii et utilisations de ces anticorps

Country Status (1)

Country Link
WO (1) WO2006100679A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595731A (en) * 2009-03-19 2013-09-27 Univ Queensland Targets for growth factor signalling and methods of therapy
EP2603524A1 (fr) 2010-08-14 2013-06-19 AbbVie Inc. Protéines de liaison bêta-amyloïdes
GB201209096D0 (en) * 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB202115121D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115127D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
TW202334240A (zh) 2021-11-18 2023-09-01 比利時商Ｕｃｂ生物製藥公司 治療進行性慢性間質性肺部疾病之方法
GB202116665D0 (en) 2021-11-18 2022-01-05 UCB Biopharma SRL Method for the treatment of a scleroderma disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004245A1 (fr) * 1996-07-25 1998-02-05 The Victoria University Of Manchester Utilisation de modulateurs de la transglutaminase pour favoriser la cicatrisation
US6794414B1 (en) * 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004245A1 (fr) * 1996-07-25 1998-02-05 The Victoria University Of Manchester Utilisation de modulateurs de la transglutaminase pour favoriser la cicatrisation
US6794414B1 (en) * 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARZARI R. ET AL.: "Molecular Dissection of the Tissue Transglutaminase Autoantibody Response in Celiac Disease", THE JOURNAL OF IMMUNOLOGY, vol. 166, 2001, pages 4170 - 4176, XP003009550 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
WO2006100679A2 (fr) 2006-09-28

Similar Documents

Publication Publication Date Title
WO2006100679A3 (fr) Anticorps de recombinaison diriges contre la transglutaminase humaine de type ii et utilisations de ces anticorps
WO2007109221A3 (fr) Methodes de reduction de l'agregation des proteines
EP2175834B8 (fr) Formulation de protéine de fusion glp-1-fc
WO2007087068A3 (fr) Inhibiteurs de tyrosine kinase et leurs utilisations
WO2005105780A3 (fr) Compositions utiles en tant qu'inhibiteurs de la rock et d'autres proteines kinases
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
WO2006034373A3 (fr) Variants et variants chimiquement modifies de phenylalanine ammonia-lyase
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
WO2006138418A3 (fr) Amelioration de la performance cognitive avec des activateurs de sirtuine
WO2008115469A3 (fr) Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
WO2006119467A3 (fr) Modification d'activite de proteine
EA200870019A1 (ru) Лактамовые соединения и способы их применения
WO2007061939A3 (fr) Dérivés de métabolites de l'inhibiteur de hdac fk228
WO2007011693A3 (fr) Compositions de cellules souches derivees du placenta, utilisees dans le traitement de cancers
WO2005103050A3 (fr) Azaindoles utiles en tant qu'inhibiteurs de la proteine serine/threonine kinase superhelice de la famille rho (rock) et d'autres proteines kinases
WO2006110819A3 (fr) Formes variantes de l'urate oxydase et leur utilisation
PL384263A1 (pl) Wariant oksydazy moczanowej i jego zastosowanie
WO2007092312A3 (fr) Compositions pour traitement cutane topique
WO2006111524A3 (fr) Variantes de l'il-21
WO2007091250A3 (fr) Enzymotherapie de remplacement pour le traitement des maladies lysosomiales
WO2006089114A3 (fr) Procedes et compositions pour le traitement d'un sujet souffrant d'un etat a mediation assuree par la toxine de l'anthrax
WO2006060680A3 (fr) Variants de la proteine mda-7 presentant une activite antiproliferative
WO2006020680A3 (fr) Composes heterocycliques comme agents pharmaceutiques
WO2006114105A8 (fr) Methodes permettant de traiter les saignements
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06711341

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6711341

Country of ref document: EP